$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000100069421000020 Filed on November 05, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$222.2M	$178.8M	$157.0M
YoY Change	-20.56%	13.9%	6163.42%
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$178.8M
YoY Change
Gross Profit Margin		100.0%
Selling, General & Admin	$84.21M	$77.79M	$56.90M
YoY Change	37.38%	36.72%	620.25%
% of Gross Profit		43.5%
Research & Development	$963.0M	$408.2M	$294.1M
YoY Change	140.02%	38.8%	1480.18%
% of Gross Profit		228.24%
Depreciation & Amortization	$3.672M	$4.262M	$1.200M
YoY Change	104.0%	255.17%	50.0%
% of Gross Profit		2.38%
Operating Expenses	$1.047B	$408.2M	$294.1M
YoY Change	126.42%	38.8%	1480.18%
Operating Profit		-$307.1M	-$193.9M
YoY Change		58.37%	1194.07%
Interest Expense	-$5.035M	$5.182M	$4.460M
YoY Change	36.08%	16.19%	31.06%
% of Operating Profit
Other Income/Expense, Net	$331.0K	-$4.394M	$952.0K
YoY Change	-96.32%	-561.55%	18940.0%
Pretax Income	-$829.7M	-$316.4M	-$197.3M
YoY Change	367.16%	60.35%	996.17%
Income Tax	$16.61M	$6.041M	$0.00
% Of Pretax Income
Net Earnings	-$846.3M	-$322.4M	-$197.3M
YoY Change	376.51%	63.41%	993.55%
Net Earnings / Revenue	-380.87%	-180.29%	-125.66%
Basic Earnings Per Share		-$4.31	-$3.21
Diluted Earnings Per Share	-$11.18M	-$4.31	-$3.21
COMMON SHARES
Basic Shares Outstanding	75.61M shares	74.75M shares	61.55M shares
Diluted Shares Outstanding		74.75M shares	61.55M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.515B	$1.937B	$504.0M
YoY Change	113.1%	284.33%	607.87%
Cash & Equivalents	$1.515B	$1.937B	$334.2M
Short-Term Investments	$1.057B	$1.457B	$297.6M
Other Short-Term Assets	$53.49M	$127.2M	$151.1M
YoY Change	453.62%	-15.8%	744.13%
Inventory	$8.872M
Prepaid Expenses
Receivables	$455.0M	$110.0M	$16.20M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.155B	$2.174B	$671.2M
YoY Change	72.66%	223.92%	654.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$228.7M	$214.8M	$131.8M
YoY Change	27.09%	62.9%	593.86%
Goodwill	$131.5M	$132.0M	$126.9M
YoY Change	-2.88%	3.98%
Intangibles	$4.770M	$5.027M	$5.332M
YoY Change	-16.68%	-5.72%
Long-Term Investments
YoY Change
Other Assets	$16.57M	$38.34M	$8.294M
YoY Change	25.33%	362.26%	654.0%
Total Long-Term Assets	$421.6M	$391.8M	$272.8M
YoY Change	26.13%	43.61%	259.9%
TOTAL ASSETS
Total Short-Term Assets	$2.155B	$2.174B	$671.2M
Total Long-Term Assets	$421.6M	$391.8M	$272.8M
Total Assets	$2.577B	$2.566B	$944.0M
YoY Change	62.83%	171.81%	472.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$127.1M	$59.56M	$15.10M
YoY Change	133.84%	294.54%	259.45%
Accrued Expenses	$673.7M	$323.9M	$78.81M
YoY Change	390.38%	310.94%	432.51%
Deferred Revenue	$1.400B
YoY Change	412.39%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$130.5M	$104.0M	$55.90M
YoY Change	23.26%	86.02%
Total Short-Term Liabilities	$2.390B	$1.753B	$239.2M
YoY Change	312.36%	632.98%	1007.49%
LONG-TERM LIABILITIES
Long-Term Debt	$323.5M	$323.1M	$384.8M
YoY Change	-10.67%	-16.03%	20.14%
Other Long-Term Liabilities	$42.12M	$28.09M	$11.26M
YoY Change	212.47%	149.41%	-12.02%
Total Long-Term Liabilities	$42.12M	$28.09M	$11.26M
YoY Change	212.47%	149.41%	-96.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.390B	$1.753B	$239.2M
Total Long-Term Liabilities	$42.12M	$28.09M	$11.26M
Total Liabilities	$2.928B	$2.105B	$637.8M
YoY Change	206.55%	230.0%	79.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.618B	-$2.772B	-$1.697B
YoY Change	93.04%	63.36%
Common Stock	$764.0K	$760.0K	$633.0K
YoY Change	7.0%	20.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$85.10M	$79.13M	$41.21M
YoY Change	103.56%	92.04%
Treasury Stock Shares	592.0K shares	557.7K shares	$391.4K
Shareholders Equity	-$351.7M	$461.3M	$106.4M
YoY Change
Total Liabilities & Shareholders Equity	$2.577B	$2.566B	$944.0M
YoY Change	62.83%	171.81%	472.83%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$846.3M	-$322.4M	-$197.3M
YoY Change	376.51%	63.41%	993.55%
Depreciation, Depletion And Amortization	$3.672M	$4.262M	$1.200M
YoY Change	104.0%	255.17%	50.0%
Cash From Operating Activities	-$342.4M	-$142.1M	-$6.500M
YoY Change	166.47%	2086.82%	-79.88%
INVESTING ACTIVITIES
Capital Expenditures	-$16.36M	-$12.19M	-$8.700M
YoY Change	-61.04%	40.11%	2800.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$91.90M
YoY Change	-100.0%	-100.0%	-602.19%
Cash From Investing Activities	-$16.36M	-$12.19M	-$100.8M
YoY Change	-47.38%	-87.91%	-660.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-60.71M	-15.72M	-22.30M
YoY Change	-115.01%	-29.51%	-285.83%
NET CHANGE
Cash From Operating Activities	-342.4M	-142.1M	-6.500M
Cash From Investing Activities	-16.36M	-12.19M	-100.8M
Cash From Financing Activities	-60.71M	-15.72M	-22.30M
Net Change In Cash	-419.5M	-170.1M	-129.6M
YoY Change	-271.22%	31.21%	5534.78%
FREE CASH FLOW
Cash From Operating Activities	-$342.4M	-$142.1M	-$6.500M
Capital Expenditures	-$16.36M	-$12.19M	-$8.700M
Free Cash Flow	-$326.0M	-$130.0M	$2.200M
YoY Change	276.93%	-6006.95%	-106.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-26770
	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	City Area Code CityAreaCode	(240)
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-2816046
	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 Firstfield Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg
	dei	Entity Address Country EntityAddressCountry	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20878
	dei	Local Phone Number LocalPhoneNumber	268-2000
	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 per share
	dei	Trading Symbol TradingSymbol	NVAX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	75608073	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1936998000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553398000	USD
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	157649000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	8175000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	93880000	USD
CY2021Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	75283000	USD
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	262012000	USD
CY2021Q3	nvax	Unbilled Services UnbilledServices	34678000	USD
CY2020Q4	nvax	Unbilled Services UnbilledServices	0	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	119047000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	181264000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	2174181000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1248203000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1653000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1460000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214751000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	179954000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5027000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5725000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	131989000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	135379000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	38340000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11758000	USD
CY2021Q3	us-gaap	Assets Assets	2565941000	USD
CY2020Q4	us-gaap	Assets Assets	1582479000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	59564000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	54332000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	323867000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	142468000	USD
CY2021Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1262360000	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	273228000	USD
CY2021Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	103987000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	105862000	USD
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3637000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3782000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1753415000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	579672000	USD
CY2021Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	323102000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	322035000	USD
CY2021Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	40083000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28088000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13480000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	2104605000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	955270000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	2000000	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	2000000	shares
CY2021Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75973523	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	75415774	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71350365	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70953739	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	760000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	714000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3310513000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2535476000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2771666000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1874199000	USD
CY2021Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	557749	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	396626	shares
CY2021Q3	us-gaap	Treasury Stock Value TreasuryStockValue	79132000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	41806000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	861000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7024000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	461336000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627209000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2565941000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1582479000	USD
CY2021Q3	us-gaap	Revenues Revenues	178844000	USD
CY2020Q3	us-gaap	Revenues Revenues	157024000	USD
	us-gaap	Revenues Revenues	924090000	USD
	us-gaap	Revenues Revenues	195939000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	408195000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	294087000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1571551000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	345828000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	77793000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	56879000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	214144000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	83977000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	485988000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	350966000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1785695000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	429805000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-307144000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-193942000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-861605000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-233866000	USD
CY2021Q3	us-gaap	Investment Income Net InvestmentIncomeNet	330000	USD
CY2020Q3	us-gaap	Investment Income Net InvestmentIncomeNet	140000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	1061000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	872000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	5182000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	4460000	USD
	us-gaap	Interest Expense InterestExpense	15989000	USD
	us-gaap	Interest Expense InterestExpense	11266000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4394000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	900000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	952000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8328000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3565000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-316390000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-197310000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-884861000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-240695000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6041000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12606000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-322431000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-197310000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-897467000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-240695000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.31
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.31
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	7000000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.21
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.39
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.39
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74745000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74745000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61554000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61554000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73972000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73972000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54810000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54810000	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-322431000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-197310000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-897467000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-240695000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-26000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-9000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	18000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3309000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	8226000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-6154000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	7495000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3309000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	8200000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6163000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	7513000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-325740000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-189110000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-903630000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-233182000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	745562000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	45274000	USD
CY2021Q3	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	-3760000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3309000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-322431000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	461336000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	184526000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	65705000	USD
CY2020Q3	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	-11871000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	725000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	57190000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-26000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	8226000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-197310000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	106440000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627209000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	151457000	USD
	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	21441000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7292000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	564859000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-9000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6154000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-897467000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	461336000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-186017000	USD
	nvax	Stock Issued During Period Value Preferred Stock Beneficial Conversion Increase Decrease StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	77602000	USD
	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	-2916000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	5870000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	450953000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	18000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7495000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-240695000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	106440000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-897467000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-240695000	USD
	nvax	Depreciation And Amortization Otherthan Right Of Use Asset DepreciationAndAmortizationOtherthanRightOfUseAsset	8989000	USD
	nvax	Depreciation And Amortization Otherthan Right Of Use Asset DepreciationAndAmortizationOtherthanRightOfUseAsset	3091000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	151457000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	77602000	USD
	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	17117000	USD
	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	187193000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2739000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3051000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-209221000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	78788000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	180708000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	60540000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	992590000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	80135000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	665354000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	86027000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	41122000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	12610000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	164204000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2167000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	266330000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	159807000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	96488000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	116518000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-346656000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	199822000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	564859000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	447070000	USD
	nvax	Payments For Proceeds From Stock Options Exercised PaymentsForProceedsFromStockOptionsExercised	-21441000	USD
	nvax	Payments For Proceeds From Stock Options Exercised PaymentsForProceedsFromStockOptionsExercised	1316000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	63876000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	65424000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	522424000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	580152000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-6208000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1298088000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	319556000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648738000	USD
CY2020Q4	us-gaap	Security Deposit SecurityDeposit	1500000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82180000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1946826000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401736000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	3883000	USD
	nvax	Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability	34914000	USD
	nvax	Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability	188362000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7884000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6189000	USD
	us-gaap	Interest Paid Net InterestPaidNet	17768000	USD
	us-gaap	Interest Paid Net InterestPaidNet	12188000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6041000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	Organization<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiaries, including Novavax AB and Novavax CZ, the “Company”) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The Company’s vaccine candidates, including both its coronavirus vaccine candidate, NVX-CoV2373, and its lead influenza vaccine candidate, NanoFlu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis and may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or traditional vaccines. NVX-CoV2373 and NanoFlu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> include the use of the Company's proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">™ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">adjuvant.</span>
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div>
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1936998000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553398000	USD
CY2021Q3	us-gaap	Security Deposit SecurityDeposit	1500000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1936998000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553398000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	8175000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	93880000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1653000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1460000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1946826000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648738000	USD
CY2021Q3	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	6000000	USD
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	12600000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	157640000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	157649000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	135379000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-3390000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	425000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	425000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	131989000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12332000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7305000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5027000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	13208000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7483000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5725000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	106000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	425000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	425000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	425000	USD
CY2021Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11400000	USD
CY2021Q3	nvax	Long Term Supply Agreement Incremental Borrowing Rate LongTermSupplyAgreementIncrementalBorrowingRate	0.065
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	111300000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	325500000	USD
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	4400000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	17100000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	19400000	USD
CY2020Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	19400000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	187200000	USD
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	187200000	USD
CY2021Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1600000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5600000	USD
CY2020Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000000	USD
	nvax	Increase Decrease Right Of Use Asset Obtained In Exchange For Operating Lease Liability IncreaseDecreaseRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	17800000	USD
CY2016Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	10000000	USD
CY2016Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	325000000	USD
CY2016Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	10000000	USD
CY2016Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P7Y
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	325000000	USD
CY2020Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	325000000	USD
CY2021Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1898000	USD
CY2020Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2965000	USD
CY2021Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	323102000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	322035000	USD
CY2021Q3	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0375
CY2021Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3047000	USD
CY2021Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3047000	USD
CY2020Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3047000	USD
CY2020Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3047000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9141000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9141000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9141000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9141000	USD
CY2021Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	356000	USD
CY2021Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	356000	USD
CY2020Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	356000	USD
CY2020Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	356000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1068000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1068000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1068000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	381000000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1068000	USD
CY2021Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	3403000	USD
CY2020Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	3403000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	10209000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	10209000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	203.51
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	102.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	156.86
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	78.78
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	673000000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	212000000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	164000000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45274000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	65705000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	151457000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	77602000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	209000000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2020Q3	us-gaap	Revenues Revenues	157024000	USD
CY2021Q3	us-gaap	Revenues Revenues	178844000	USD
	us-gaap	Revenues Revenues	924090000	USD
	us-gaap	Revenues Revenues	195939000	USD
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	262012000	USD
	nvax	Receivables Net Current Additions ReceivablesNetCurrentAdditions	1601385000	USD
	nvax	Receivables Current Net Deductions ReceivablesCurrentNetDeductions	1788114000	USD
CY2021Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	75283000	USD
CY2020Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	0	USD
	nvax	Unbilled Receivables Current Additions UnbilledReceivablesCurrentAdditions	635975000	USD
	nvax	Unbilled Receivables Current Deductions UnbilledReceivablesCurrentDeductions	601297000	USD
CY2021Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	34678000	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	273228000	USD
	nvax	Deferred Revenue Current Additions DeferredRevenueCurrentAdditions	1277247000	USD
	nvax	Deferred Revenue Current Deductions DeferredRevenueCurrentDeductions	288115000	USD
CY2021Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1262360000	USD
CY2021Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1300000000	USD
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	7200000000	USD
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M

Files In Submission

Name	View Source	Status
0001000694-21-000020-index-headers.html	Edgar Link	pending
0001000694-21-000020-index.html	Edgar Link	pending
0001000694-21-000020.txt	Edgar Link	pending
0001000694-21-000020-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_01.jpg	Edgar Link	pending
image_02.jpg	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvax-20210930.htm	Edgar Link	pending
nvax-20210930.xsd	Edgar Link	pending
nvax-20210930xex101.htm	Edgar Link	pending
nvax-20210930xex102.htm	Edgar Link	pending
nvax-20210930xex103.htm	Edgar Link	pending
nvax-20210930xex104.htm	Edgar Link	pending
nvax-20210930xex105.htm	Edgar Link	pending
nvax-20210930xex106.htm	Edgar Link	pending
nvax-20210930xex107.htm	Edgar Link	pending
nvax-20210930xex108.htm	Edgar Link	pending
nvax-20210930xex311.htm	Edgar Link	pending
nvax-20210930xex312.htm	Edgar Link	pending
nvax-20210930xex321.htm	Edgar Link	pending
nvax-20210930xex322.htm	Edgar Link	pending
nvax-20210930_cal.xml	Edgar Link	unprocessable
nvax-20210930_def.xml	Edgar Link	unprocessable
nvax-20210930_g1.jpg	Edgar Link	pending
nvax-20210930_g2.jpg	Edgar Link	pending
nvax-20210930_g3.jpg	Edgar Link	pending
nvax-20210930_htm.xml	Edgar Link	completed
nvax-20210930_lab.xml	Edgar Link	unprocessable
nvax-20210930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2021 Q4 Form 10-Q Financial Statement

#000100069421000020 Filed on November 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2021 Q4 Form 10-Q Financial Statement

#000100069421000020 Filed on November 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax